glp-1 receptor agonists alternatives to ozempic and Other Drugs GLP-1 Alternatives to Ozempic: Medical
Description
Kirchgesner J, Beaugerie L, Carrat F, Andersen NN, Jess T, Schwarzinger M
A 17-month study specifically looking at its effect on obesity showed people on the highest dose of tirzepatide (15 milligrams) lost on average just over 20% of their body weight
A hallmark of MASLD progression is chronic low-grade inflammation, which plays a pivotal role in the transition from MASL to more advanced stages such as MASH, fibrosis, and cirrhosis
CKD: chronic kidney disease
In addition, the follow-up duration of ELIXA was also relatively short (2.1 years), especially when compared with the follow-up duration of 5.4 years in the REWIND trial [60, 62]
